Telix Pharmaceuticals (TLX) Stock Statistics & Valuation Metrics

Telix Pharmaceuticals has a market cap or net worth of AU$5.31B. The enterprise value is AU$6.39K.

Telix Pharmaceuticals has 339,784,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Telix Pharmaceuticals’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is 1.90%.

The current PE Ratio of Telix Pharmaceuticals is 115.9. Telix Pharmaceuticals’s PEG ratio is 2.81.

In the last 12 months, Telix Pharmaceuticals had revenue of 1.25B and earned -11.05M in profits. Earnings per share was -0.03.

In the last 12 months, operating cash flow was -21.58M and capital expenditures -67.13M, giving a free cash flow of -88.71M billion.

Telix Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Telix Pharmaceuticals upcoming earnings date is Feb 19, 2027, TBA (Confirmed).

Telix Pharmaceuticals as a current ratio of 1.43, with Debt / Equity ratio of 118.90%

In the past 12 months, Telix Pharmaceuticals has paid 2.88M in taxes.

Telix Pharmaceuticals EV to EBITDA ratio is 69.64, with an EV/FCF ratio of -49.89.

Telix Pharmaceuticals has AU$363.61M in cash and marketable securities with AU$836.98M in debt, giving a net cash position of -AU$473.37M billion.

Gross margin is 52.16%, with operating margin of 2.21%, and net profit margin of -0.89%.

The average price target for Telix Pharmaceuticals is AU$25.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy